A monoclonal antibody that binds to the type 1 interferon-alpha receptor showed an acceptable safety profile in a phase I trial for systemic sclerosis, but efficacy was less clear. Med Page Today, 02/27/2014. (Also see: Interferon-Alpha)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.